Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 124, Issue 1, Pages 6-12Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI71602
Keywords
-
Categories
Funding
- US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development
- NIH R01 [HL096376, HL097376, HL098174]
- NIH P01 [HL114453]
- US Department of Veterans Affairs
Ask authors/readers for more resources
The ubiquitin proteasome system (UPS) is an essential metabolic constituent of cellular physiology that tightly regulates cellular protein concentrations with specificity and precision to optimize cellular function. Inhibition of the proteasome has proven very effective in the treatment of multiple myeloma, and this approach is being tested for utility in other malignancies. New pharmaceuticals targeting the proteasome itself or specific proximal pathways of the UPS are in development as antiproliferatives or immunomodulatory agents. In this article, we discuss the biology of UPS-targeting drugs, their use as therapy for neoplasia, and the state of clinical and preclinical development for emerging therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available